A new peer-reviewed study in The Lancet has found that Russia’s potential coronavirus vaccine has no major side effects yet.

  • According to The Lancet, doctors in the trials have done two phase one and phase two studies at two hospitals in Russia.
  • The trials included 76 healthy volunteers from 18 to 60 years old.
  • The vaccine formulations were “safe and well tolerated,” the article said.
Related
In our opinion: A vaccine won’t save lives, but Americans getting vaccinated will
In our opinion: Forget Russia’s vaccine, spend billions more on the others
  • The trials — which lasted 42 days and had 38 adults each — “did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” the study’s authors wrote.
  • “Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.”
Related
Who gets a vaccine?

What to consider about Russia’s vaccine

Back in August, Russian President Vladimir Putin said the country had the world’s first coronavirus vaccine, as I wrote for Deseret.com. He said he even tested the vaccine on his daughter.

  • “As far as I know, a vaccine against a new coronavirus infection has been registered this morning, for the first time in the world,” he said at a meeting with members of the government, RIA Novosti reported.
Related
You might need two doses of the COVID-19 vaccine

But Dr. Scott Gottlieb, the former U.S. Food and Drug Administration commissioner, told CNBC he wouldn’t use the COVID-19 vaccine from Russia unless there was a clinical trial that proved it was successful.

  • “They’ve cleared the equivalent, really, of a phase 1 clinical trial in terms of putting it in 100 to maybe as many as 300 patients so it needs to be evaluated in a large-scale clinical trial.”
Join the Conversation
Looking for comments?
Find comments in their new home! Click the buttons at the top or within the article to view them — or use the button below for quick access.